VANCOUVER, BRITISH COLUMBIA--(Marketwired - Oct. 7, 2015) - VANC Pharmaceuticals Inc. ("VANC" or the "Company") (TSX VENTURE:NPH)(OTCQB:NUVPF), a pharmaceutical company focused on the Canadian generic drug and over-the-counter (the "OTC") markets, is pleased to announce that it has listed multiple products in Provincial formularies of British Columbia, Alberta, Saskatchewan, Manitoba, Ontario and Quebec.

The Provincial formularies list drugs for which particular public or private health plans will pay all or part of the cost and the circumstances in which the coverage is available. Each Province maintains the formulary autonomously and decides regarding which drugs and which individuals are covered.

"The listing on Provincial formularies across Canada is a major step in commercializing our generics portfolio across Canada. We have now registered a minimum of 7 molecules and 20 stock keeping units (the "SKUs") in six Provinces. The next step will be to expand our sales force through the hiring of reps in each of the Provinces," said Arun Nayyar, CEO of VANC.

Table 1.0 lists the number of molecules listed in each provincial formulary. The drugs having no coverage from provincial health care plans are considered to be non-benefit drugs.

Province Listed Non-Benefit Total Number
of Molecules
British Columbia 14 4 18
Alberta 15 7 22
Saskatchewan 14 4 18
Manitoba 1 1 2
Ontario 14 - 14
Quebec 8 1 9

Table 1.0

A full listing of the molecules and SKUs listed in each of the provinces can be seen at

The Company will provide updates on commercialization and additional product listings across Canada during Q4-2015.

On behalf of:

VANC Pharmaceuticals Inc.

Aman Parmar, CFO and Director

Cautionary Note Regarding Forward-looking Statements: Information in this press release that involves VANC's expectations, plans, intentions or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. VANC generally uses words such as "outlook," "will," "could," "would," "might," "remains," "to be," "plans," "believes," "may," "expects," "intends," "anticipates," "estimate," "future," "plan," "positioned," "potential," "project," "remain," "scheduled," "set to," "subject to," "upcoming," and similar expressions to help identify forward-looking statements. The forward-looking statements in this release are based upon information available to VANC as of the date of this release, and VANC assumes no obligation to update any such forward-looking statements. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of VANC and are subject to risks, uncertainties and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information:

VANC Pharmaceuticals
IR: 604-566-9233

VANC Pharmaceuticals
Aman Parmar
CFO and Director